Evidence map›Paper›PMID 26416686›Full record

ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2015

Cell-based therapy technology classifications and translational challenges.

Natalie M Mount, Stephen J Ward, Panos Kefalas, Johan Hyllner

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Cell-Based Therapies for Solid Tumors: Challenges and Advances.International journal of molecular sciences · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Natalie M MountCell Therapy Catapult, Guy's Hospital, London SE1 9RT, UK natalie.mount@ct.catapult.org.uk.
Stephen J WardCell Therapy Catapult, Guy's Hospital, London SE1 9RT, UK.
Panos KefalasCell Therapy Catapult, Guy's Hospital, London SE1 9RT, UK.
Johan HyllnerCell Therapy Catapult, Guy's Hospital, London SE1 9RT, UK Division of Biotechnology, IFM, Linköping University, Linköping 581 83, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell therapies offer the promise of treating and altering the course of diseases which cannot be addressed adequately by existing pharmaceuticals. Cell therapies are a diverse group across cell types and therapeutic indications and have been an active area of research for many years but are now strongly emerging through translation and towards successful commercial development and patient access. In this article, we present a description of a classification of cell therapies on the basis of their underlying technologies rather than the more commonly used classification by cell type because the regulatory path and manufacturing solutions are often similar within a technology area due to the nature of the methods used. We analyse the progress of new cell therapies towards clinical translation, examine how they are addressing the clinical, regulatory, manufacturing and reimbursement requirements, describe some of the remaining challenges and provide perspectives on how the field may progress for the future.

Indexed as

AnimalsBiotechnologyCell- and Tissue-Based TherapyCell Line, TransformedCellular Reprogramming TechniquesGenetic VectorsHumansRNA EditingTissue EngineeringTranslational Research, Biomedicalcell therapyclinical trialmanufacturingregulationreimbursementtranslation

Identifiers

PMID26416686
PMCPMC4634004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.